Neural Noise- A coalition of major brain-computer interface companies — Blackrock Neurotech, Precision Neuroscience, Neuralink, Synchron, and Paradromics — jointly petitioned the FDA on July 7, 2026 for greater transparency about, and possible expansion of, the agency’s Commissioner’s National Priority Voucher (CNPV) pilot program.1
- CNPV, launched by FDA in 2025, grants qualifying drug/biologic sponsors significantly shorter review periods and closer agency engagement; the BCI group asked FDA to either expand eligibility to include medical devices outright or create a parallel program specifically for medtech products.1
- Their argument: the five national health priorities that qualify a product for a CNPV voucher (responding to public health crises, breakthrough technology, large unmet needs, domestic supply-chain strength, and affordability) apply equally to devices as to drugs, and excluding devices is a “semantic classification” rather than one grounded in public health impact.1
- The group also invoked national-security framing, arguing that expanding NPV eligibility to BCI devices would help the US compete with and prevent “foreign adversaries” from dominating BCI development/commercialization and would protect sensitive American health data — tying regulatory-speed advocacy to onshoring and supply-chain-resilience arguments.1
- This is a notable moment of coordinated industry-wide policy advocacy across otherwise-competing invasive BCI companies (Blackrock, Precision, Neuralink, Synchron, Paradromics), signaling the sector’s growing lobbying maturity as multiple firms approach pivotal regulatory and commercialization milestones simultaneously.1